MAPK Signaling Pathways in Neurodegeneration

MAPK Signaling Pathways in Neurodegeneration

Introduction

The mitogen-activated protein kinase (MAPK) cascades are evolutionarily conserved signal transduction pathways that relay extracellular signals from membrane receptors to intracellular effectors controlling cell proliferation, differentiation, survival, and inflammatory responses. In the central nervous system, three principal MAPK modules — the extracellular signal-regulated kinases (ERK1/2), the c-Jun N-terminal kinases (JNK1/2/3), and the p38 MAPKs (p38α/β/γ/δ) — play distinct but interconnected roles in neuronal physiology and pathology. Aberrant activation of these cascades, particularly p38α MAPK and JNK, is now established as a key driver of neuroinflammation, tau hyperphosphorylation, synaptic dysfunction, and neuronal apoptosis across multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. [@kim2010]

Each MAPK cascade follows a three-tiered kinase architecture: a MAP kinase kinase kinase (MAP3K) phosphorylates and activates a MAP kinase kinase (MAP2K), which in turn phosphorylates and activates the terminal MAPK on its TxY activation motif. This amplification architecture enables signal specificity, integration of diverse upstream inputs, and threshold-dependent responses that are critical for distinguishing physiological signaling from pathological overactivation. [@cargnello2011]

MAPK Cascade Architecture

ERK1/2 Pathway (Ras-Raf-MEK-ERK)

MAPK Signaling Pathways in Neurodegeneration

Introduction

The mitogen-activated protein kinase (MAPK) cascades are evolutionarily conserved signal transduction pathways that relay extracellular signals from membrane receptors to intracellular effectors controlling cell proliferation, differentiation, survival, and inflammatory responses. In the central nervous system, three principal MAPK modules — the extracellular signal-regulated kinases (ERK1/2), the c-Jun N-terminal kinases (JNK1/2/3), and the p38 MAPKs (p38α/β/γ/δ) — play distinct but interconnected roles in neuronal physiology and pathology. Aberrant activation of these cascades, particularly p38α MAPK and JNK, is now established as a key driver of neuroinflammation, tau hyperphosphorylation, synaptic dysfunction, and neuronal apoptosis across multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. [@kim2010]

Each MAPK cascade follows a three-tiered kinase architecture: a MAP kinase kinase kinase (MAP3K) phosphorylates and activates a MAP kinase kinase (MAP2K), which in turn phosphorylates and activates the terminal MAPK on its TxY activation motif. This amplification architecture enables signal specificity, integration of diverse upstream inputs, and threshold-dependent responses that are critical for distinguishing physiological signaling from pathological overactivation. [@cargnello2011]

MAPK Cascade Architecture

ERK1/2 Pathway (Ras-Raf-MEK-ERK)

The ERK1/2 pathway is classically activated by growth factors, neurotrophins (BDNF, GDNF, NGF), and synaptic activity through Ras GTPase → Raf (MAP3K) → MEK1/2 (MAP2K) → ERK1/2 (MAPK). In neurons, ERK signaling is essential for:

• Synaptic plasticity: ERK activation is required for long-term potentiation (LTP) and memory consolidation through phosphorylation of CREB, Elk-1, and MSK1 transcription factors. [@thomas2004]
• Neuronal survival: ERK phosphorylates and inactivates the pro-apoptotic BCL-2 family member BAD, promotes expression of anti-apoptotic proteins, and activates the RSK→CREB survival pathway
• Neurite outgrowth: Sustained ERK activation drives neuronal differentiation through transcriptional programs distinct from those activated by transient ERK signals

p38 MAPK Pathway

The p38 MAPK family, particularly p38α (MAPK14) and p38β (MAPK11), is activated by cellular stress signals including oxidative stress, pro-inflammatory cytokines (TNF-α, IL-1β), and pathogen-associated molecular patterns through MAP3Ks (ASK1, TAK1, MEKK3) → MKK3/MKK6 (MAP2K) → p38 (MAPK). In the brain, p38 MAPK is the primary stress-activated kinase implicated in neurodegeneration:

• Neuroinflammation: p38α drives transcription and stabilization of pro-inflammatory cytokine mRNAs in microglia. It is essential for NF-κB-dependent transcription of IL-6, TNF-α, IL-1β, and iNOS. [@lee2017]
• Tau phosphorylation: p38 directly phosphorylates tau at multiple AD-relevant epitopes including Thr181, Ser199, Thr205, Thr231, and Ser396. [@reynolds2000]
• Synaptic dysfunction: p38 activation in dendritic spines promotes AMPA receptor endocytosis and long-term depression (LTD), contributing to synaptic weakening
• Microglial activation: p38α is the dominant isoform mediating classical (M1) microglial activation, phagocytosis, and cytokine production

JNK Pathway

The JNK pathway (JNK1/2/3) is activated by a broad range of stress signals through MAP3Ks (ASK1, MLK3, DLK, MEKK1) → MKK4/MKK7 → JNK. JNK3 is predominantly expressed in the brain and has been strongly implicated in neurodegeneration:

• Apoptosis: JNK phosphorylates the transcription factor c-Jun, promoting expression of pro-apoptotic genes (Bim, FasL, DP5/HRK). JNK also directly phosphorylates BCL-2 family members to trigger mitochondrial outer membrane permeabilization. [@bhatt2019]
• Tau phosphorylation: JNK phosphorylates tau at multiple epitopes and promotes neurofibrillary tangle formation
• Axonal degeneration: The DLK→MKK4→JNK pathway is a master regulator of Wallerian degeneration and axonal injury signaling
• APP processing: JNK activation increases APP phosphorylation at Thr668, promoting amyloidogenic processing and Aβ production

MAPK Dysregulation in Specific Diseases

Alzheimer's Disease

MAPK dysregulation is a prominent feature of AD pathology at multiple levels:

p38 MAPK activation: Phosphorylated p38 is elevated in AD brain tissue, co-localizing with neurofibrillary tangles and activated microglia surrounding amyloid plaques. The p38 MAPK-MK2/3 axis drives neuroinflammatory cytokine production that creates a self-amplifying cycle: Aβ activates microglial p38 → cytokine release → neuronal p38 activation → tau hyperphosphorylation → further microglial activation. [@thakur2024]

JNK activation: JNK3 knockout mice show reduced Aβ levels, tau phosphorylation, and neuronal loss in AD models. JNK activation in AD correlates with Braak staging, increasing from early entorhinal involvement (Braak I-II) through limbic (III-IV) to neocortical stages (V-VI). [@bhatt2019]

ERK paradox: While ERK signaling supports neuronal survival, early and sustained ERK activation is detected in vulnerable hippocampal neurons in AD, potentially driving pathological tau phosphorylation. Phosphorylated ERK1/2 co-localizes with early-stage tangles but not mature tangles, suggesting a role in disease initiation. [@ferrer2001]

Parkinson's Disease

In Parkinson's disease, MAPK cascades are dysregulated in both dopaminergic neurons and surrounding glia:

• p38α in microglia: Alpha-synuclein aggregates released from degenerating neurons activate microglial p38α through TLR2/4 signaling, driving production of TNF-α, IL-1β, and reactive oxygen species. Inhibition of p38α reduced neuroinflammation and ameliorated synaptic, neurodegenerative, and motor behavioral deficits in transgenic mice overexpressing human α-synuclein. [@ittner2023]
• JNK in dopaminergic death: JNK activation by oxidative stress (6-OHDA, MPTP) and LRRK2 gain-of-function mutations triggers c-Jun-dependent apoptosis in substantia nigra pars compacta neurons
• ERK in neuroprotection: GDNF and BDNF signaling through ERK is neuroprotective for dopaminergic neurons; loss of ERK signaling contributes to neuronal vulnerability

Amyotrophic Lateral Sclerosis

In ALS, MAPK pathways are activated by mutant SOD1, TDP-43 aggregates, and C9orf72 repeat expansions:

• p38 in motor neurons: p38 activation is an early event in SOD1-G93A mouse motor neurons, preceding symptom onset. p38 promotes phosphorylation of neurofilaments (NEFL, NEFH), disrupting axonal transport. [@dewil2007]
• ASK1-p38 axis: Apoptosis signal-regulating kinase 1 (ASK1) is activated by oxidative stress and mutant SOD1, triggering the p38 and JNK cascades in motor neurons
• DLK-JNK in axonal degeneration: The dual leucine zipper kinase (DLK) → MKK4 → JNK pathway drives axonal degeneration in ALS models; DLK inhibition prolongs survival in SOD1 mutant mice

Huntington's Disease

Mutant huntingtin activates both JNK and p38 in medium spiny neurons:

• JNK3 phosphorylates mutant huntingtin, enhancing its toxicity and aggregation
• p38 activation contributes to transcriptional dysregulation through phosphorylation of CREB and MEF2 transcription factors
• ERK activation by BDNF signaling is impaired in HD due to reduced cortical BDNF expression and transport, removing a key pro-survival signal from striatal neurons

Therapeutic Targeting of MAPK Pathways

p38 MAPK Inhibitors

p38α MAPK has emerged as one of the most promising kinase targets in neurodegeneration. Multiple classes of inhibitors are in development:

| Compound | Target | Stage | Key Results |
|----------|--------|-------|-------------|
| Neflamapimod (VX-745) | p38α | Phase 2 (AD/DLB) | Improved episodic memory in early AD; reduced CSF tau. [@alam2023] |
| MW150 | p38α | Preclinical | Brain-penetrant; reduces neuroinflammation in AD/PD models |
| PRZ-18002 | p38 (PROTAC degrader) | Preclinical | Intranasal delivery; reduces pTau, Aβ, and microglial activation in 5xFAD mice. [@bhatt2023] |
| Skepinone-L | p38α | Preclinical | Selective; restores p38γ neuroprotection in PD models |

JNK Inhibitors

• SP600125: Non-selective JNK inhibitor with neuroprotective effects in AD and stroke models; limited selectivity hinders clinical development
• CEP-1347: MLK inhibitor (upstream of JNK); failed in a Parkinson's disease trial (PRECEPT) due to lack of efficacy, though this may reflect timing rather than target validity
• DLK inhibitors: Sanofi's GDC-0134 and other DLK inhibitors are in clinical development for ALS, targeting the axonal degeneration pathway

ERK Pathway Modulation

Rather than direct ERK inhibition, therapeutic strategies focus on restoring appropriate ERK signaling:

• BDNF and GDNF gene therapy to restore ERK-dependent survival signaling in PD
• TrkB receptor agonists (7,8-dihydroxyflavone) to activate BDNF→ERK pathway
• MEK inhibitors (trametinib) show paradoxical neuroprotection in some models by reducing pathological ERK-mediated tau phosphorylation

MAPK Signaling Cascade Diagram

Crosstalk with Other Pathways

MAPK pathways do not function in isolation but interact extensively with other signaling cascades relevant to neurodegeneration:

• NF-κB: p38 and JNK activate NF-κB signaling in microglia, amplifying inflammatory gene expression. TAK1 serves as a shared MAP3K for both MAPK and NF-κB pathways. [@kumar2025]
• PI3K/Akt: ERK and Akt pathways converge on common substrates (BAD, GSK-3β, mTOR) but often exert opposing effects on cell fate. In many neurodegenerative contexts, Akt suppression co-occurs with p38/JNK activation
• AMPK: Cellular energy stress activates AMPK, which can suppress ERK signaling while activating p38, shifting the balance toward stress responses
• Calcium signaling: Ca²⁺-dependent activation of CaMKII and calcineurin modulates MAPK cascades at multiple levels; NMDA receptor-mediated Ca²⁺ influx activates both ERK (synaptic) and p38/JNK (extrasynaptic) pathways
• CDK5: p38 MAPK and CDK5 synergistically phosphorylate tau; CDK5/p25 activates ASK1 to further amplify p38 signaling. [@sahoo2025]

Cross-Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Tau Protein](/proteins/tau-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [CDK5 — Cyclin-Dependent Kinase 5](/proteins/cdk5)
• [GSK3B — Glycogen Synthase Kinase 3 Beta](/genes/gs3kb)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Tau Protein](/proteins/tau-protein)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [CDK5](/proteins/cdk5)
• [GSK3B](/genes/gs3kb)

External Links

• [MAPK Signaling Pathway — KEGG](https://www.genome.jp/kegg-bin/show_pathway?hsa04010)
• [p38 MAPK Cascade — Reactome](https://reactome.org/PathwayBrowser/#/R-HSA-171007)
• [ERK/MAPK Signaling — Reactome](https://reactome.org/PathwayBrowser/#/R-HSA-5684996)
• [Allen Brain Atlas](https://human.brain-map.org/)
• [BrainSpan Atlas](https://brainspan.org/)

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 14 references |
| Replication | Multiple studies |
| Effect Sizes | Context-dependent |
| Contradicting Evidence | Some |
| Mechanistic Completeness | 60% |

Overall Confidence: 50%

Pathway Diagram

The following diagram shows the key molecular relationships involving MAPK Signaling Pathways in Neurodegeneration discovered through SciDEX knowledge graph analysis: